Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for maximum therapeutic effect, are licensed for the treatment of influenza. However, oseltamivir-resistant mutants of seasonal H1N1 and highly pathogenic H5N1 avian influenza...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-02-01
|
Series: | PLoS Pathogens |
Online Access: | http://europepmc.org/articles/PMC2829070?pdf=render |